Outcomes of COVID‐19 vaccination in 323 patients with clonal and non‐clonal mast cell activation disorders-Reference-Cited by-同舟云学术

Outcomes of COVID‐19 vaccination in 323 patients with clonal and non‐clonal mast cell activation disorders

Published:2022-08-23 Issue:1 Volume:78 Page:301-304
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Giannetti Matthew P.¹²^ORCID,Olivieri Francesco³^ORCID,Godwin Grace¹,Weller Emma¹,Nicoloro‐SantaBarbara Jennifer²⁴,Bonadonna Patrizia³^ORCID,Zanotti Roberta⁵,Zanoni Giovanna⁶,Hartmann Karin⁷⁸,Castells Mariana¹²

Affiliation:

1. Division of Allergy and Clinical Immunology Brigham and Women's Hospital Boston Massachusetts USA

2. Harvard Medical School Boston Massachusetts USA

3. Allergy Unit Verona University Hospital Verona Italy

4. Department of Psychiatry Brigham and Women's Boston Massachusetts USA

5. Department of Medicine, Section of Hematology Verona Italy

6. Immunology Unit Verona University Hospital Verona Italy

7. Division of Allergy University Hospital Basel and University of Basel Basel Switzerland

8. Department of Biomedicine University Hospital Basel and University of Basel Basel Switzerland

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15476

Reference7 articles.

1. Surveillance for Adverse Events After COVID-19 mRNA Vaccination

2. SARS-CoV-2 Positivity on or After 9 Days Among Quarantined Student Contacts of Confirmed Cases

3. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome

4. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis

5. COVID-19 vaccination in the setting of mastocytosis—Pfizer-BioNTech mRNA vaccine is safe and well tolerated

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis;Acta Médica Portuguesa;2024-03-01

2. Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy;Vaccines;2024-02-16

3. COVID‐19 infection and vaccination in 92 pediatric patients with cutaneous mastocytosis: A retrospective, cross‐sectional study;Pediatric Dermatology;2024-02-02

4. Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis;Diagnostics;2024-01-05

5. Post‐COVID‐19 Vaccination Trimester Evaluation in Mastocytosis: A Single‐Center Real‐Life Experience;Asthma Allergy Immunology;2023-12